The aim of the present study was to compare the severity of cerebellar ataxia as measured by the International Cooperative Ataxia Rating Scale (ICARS) by Trouillas et al. [ J Neurol Sci 1997;145:205–211] with the cerebellar volume in chronic cerebellar disease. Fifteen patients with pure cerebellar degeneration were investigated. Seven patients suffered from spinocerebellar ataxia type 6, 5 from idiopathic late-onset cerebellar ataxia, 2 from autosomal dominant cerebellar ataxia type III and 1 from episodic ataxia type 2. Volumetric analysis was based on individual three-dimensional MR images. Total ICARS score significantly inversely correlated with the cerebellar volume (r = –0.805, p < 0.0001), correlations between ICARS subscores and cerebellar volume were significant for upper and lower limb ataxia, ataxia of posture and gait, and dysarthria, but not for the oculomotor subscore. The results suggest that the degree of cerebellar atrophy in pure cerebellar degenerative disorders is accompanied by comparable functional impairment (i.e. degree of cerebellar ataxia).

Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, Bryer A, Diener HC, Massaquoi S, Gomez CM, Coutinho P, Ben Hamida M, Campanella G, Filla A, Schut L, Timmann D, Honnorat J, Nighoghossian N, Manyam B: International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997;145:205–211.
Klockgether T, Skalej M, Wedekind D, Luft AR, Welte D, Schulz JB, Abele M, Burk M, Laccone F, Brice A, Dichgans J: Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2, and 3. Brain 1998;121:1687–1693.
Paradiso S, Andreasen NC, O’Leary DS, Arndt S, Robinson RG: Cerebellar size and cognition: correlations with IQ, verbal memory and motor dexterity. Neuropsychiatry Neuropsychol Behav Neurol 1997;10:1–8.
Brenneis C, Bosch SM, Schocke M, Wenning GK, Poewe W: Atrophy pattern in SCA2 determined by voxel-based morphometry. Neuroreport 2003;14:1799–1802.
Guerrini L, Lolli F, Ginestroni A, Belli G, Della Nave R, Tessa C, Foresti S, Cosottini M, Piacentini S, Salvi F, Plasmati R, De Grandis D, Siciliano G, Filla A, Mascalchi M: Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study. Brain 2004;127:1785–1795.
Klockgether T, Schroth G, Diener HC, Dichgans J: Idiopathic cerebellar ataxia of late onset: natural history and MRI morphology. J Neurol Neurosurg Psychiatry 1990;53:297–305.
Campanella G, Filla A, DeFalco F, Mansi D, Durivage A, Barbeau A: Friedreich’s ataxia in the south of Italy: a clinical and biochemical survey of 23 patients. Can J Neurol Sci 1980;7:7351–357.
Winkler G, Hahn K, Aurich V, Martin A, Rodenacker K: Noise reduction in images: some recent edge-preserving methods. Pattern Recognit Image Anal1999;9:749–766.
Raz N, Gunning-Dixon F, Head D, Williamson A, Acker JD: Age and sex differences in the cerebellum and the ventral pons: a prospective study of healthy adults. Am J Neuroradiol 2001;22:1161–1167.
Woodruff-Pak DS, Vogel RW, Ewers M, Boyko OB, Lemieux SK: MRI-assessed volume of cerebellum correlates with associative learning. Neurobiol Learn Mem 2001;76:342–357.
Bürk K, Globas C, Wahl T, Bühring U, Dietz K, Zühlke C, Luft A, Schulz JB, Voigt K, Dichgans J: MRI-based volumetric differentiation of sporadic cerebellar ataxia. Brain 2004;127:175–181.
Bastian A, Thach WT: Structure and function of the cerebellum; in Manto MU, Pandolfo M (eds): The Cerebellum and Its Disorders. New York, Cambridge University Press, 2002, pp 49–68.
Lechtenberg R, Gilman S: Speech disorders in cerebellar disease. Ann Neurol 1978;34:285–290.
Straube A, Büttner U: Zerebelläre Augenbewegungsstörungen; in Huber A, Kömpf D (eds): Klinische Neuroophthalmologie. Stuttgart, Thieme, 1998, pp 566–570.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.